United Therapeutics (NASDAQ:UTHR) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday.

UTHR has been the subject of a number of other reports. Zacks Investment Research upgraded United Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 9th. HC Wainwright restated a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a research note on Thursday, October 26th. Cowen restated a “hold” rating and issued a $129.00 target price on shares of United Therapeutics in a research note on Friday, October 27th. Oppenheimer restated a “buy” rating on shares of United Therapeutics in a research note on Friday, September 8th. Finally, TheStreet downgraded United Therapeutics from a “b-” rating to a “c” rating in a research note on Friday, September 29th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. United Therapeutics has an average rating of “Hold” and a consensus price target of $136.10.

Shares of United Therapeutics (UTHR) traded up $3.33 during mid-day trading on Thursday, reaching $133.32. The company’s stock had a trading volume of 342,729 shares, compared to its average volume of 344,777. United Therapeutics has a 12 month low of $112.01 and a 12 month high of $169.89. The firm has a market capitalization of $5,617.00, a P/E ratio of 11.46 and a beta of 1.42.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, beating the Zacks’ consensus estimate of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The company had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. During the same period in the previous year, the firm posted $4.23 earnings per share. United Therapeutics’s quarterly revenue was up 9.1% compared to the same quarter last year. analysts forecast that United Therapeutics will post 12.29 EPS for the current year.

In related news, CEO Martine A. Rothblatt sold 1,232 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $133.32, for a total transaction of $164,250.24. Following the sale, the chief executive officer now owns 2,301 shares of the company’s stock, valued at $306,769.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 7,061 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $121.12, for a total value of $855,228.32. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,900 shares of company stock worth $2,919,517. Corporate insiders own 7.80% of the company’s stock.

Large investors have recently made changes to their positions in the stock. State of Wisconsin Investment Board bought a new stake in United Therapeutics during the second quarter worth approximately $5,256,000. Comerica Bank raised its holdings in United Therapeutics by 1.3% during the second quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock worth $4,635,000 after purchasing an additional 458 shares in the last quarter. River & Mercantile Asset Management LLP bought a new stake in United Therapeutics during the second quarter worth approximately $908,000. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in United Therapeutics by 2.3% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 123,016 shares of the biotechnology company’s stock worth $15,959,000 after purchasing an additional 2,762 shares in the last quarter. Finally, Captrust Financial Advisors bought a new stake in United Therapeutics during the second quarter worth approximately $925,000. 99.83% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/12/02/united-therapeutics-uthr-stock-rating-upgraded-by-valuengine.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.